NLS Pharmaceutics Statistics
Share Statistics
NLS Pharmaceutics has 3.6M
shares outstanding. The number of shares has increased by -94.3%
in one year.
| Shares Outstanding | 3.6M |
| Shares Change (YoY) | -94.3% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 22.34% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 433 |
| FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 91.33K, so 2.25% of the outstanding
shares have been sold short.
| Short Interest | 91.33K |
| Short % of Shares Out | 2.25% |
| Short % of Float | 2.51% |
| Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -73.77 and the forward
PE ratio is 0.04.
NLS Pharmaceutics's PEG ratio is
1.19.
| PE Ratio | -73.77 |
| Forward PE | 0.04 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | -101.65 |
| P/FCF Ratio | -92.72 |
| PEG Ratio | 1.19 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for NLS Pharmaceutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.23,
with a Debt / Equity ratio of -0.18.
| Current Ratio | 0.23 |
| Quick Ratio | 0.23 |
| Debt / Equity | -0.18 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.17 |
| Interest Coverage | -81.34 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,028,671.5 |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -73.42% in the
last 52 weeks. The beta is -0.22, so NLS Pharmaceutics's
price volatility has been lower than the market average.
| Beta | -0.22 |
| 52-Week Price Change | -73.42% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 3.16 |
| Relative Strength Index (RSI) | 64.29 |
| Average Volume (20 Days) | 147,228 |
Income Statement
| Revenue | n/a |
| Gross Profit | -11.41K |
| Operating Income | -11.81M |
| Net Income | -12.17M |
| EBITDA | -11.8M |
| EBIT | -11.81M |
| Earnings Per Share (EPS) | -0.32 |
Full Income StatementBalance Sheet
The company has 897.68K in cash and 1.63M in
debt, giving a net cash position of -736.07K.
| Cash & Cash Equivalents | 897.68K |
| Total Debt | 1.63M |
| Net Cash | -736.07K |
| Retained Earnings | -70.37M |
| Total Assets | 1.19M |
| Working Capital | -6.53M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.68M
and capital expenditures -4, giving a free cash flow of -9.68M.
| Operating Cash Flow | -9.68M |
| Capital Expenditures | -4 |
| Free Cash Flow | -9.68M |
| FCF Per Share | -0.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
